Kinnane Nicole
Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett Street, Melbourne, Victoria 8006, Australia.
Eur J Oncol Nurs. 2007;11 Suppl 2:S28-31. doi: 10.1016/j.ejon.2007.07.002. Epub 2007 Sep 4.
Malignant bone disease can cause clinically relevant skeletal morbidity that negatively affects quality of life. The prevalence and consequences of skeletal-related events (SREs) resulting from bone metastases, and the effects of bone metastasis therapies will be discussed.
The burden of bone disease was researched through PubMed and the proceedings of international oncology meetings.
Malignant bone disease is a potentially devastating condition that is prevalent in patients with advanced cancers. Most patients with bone metastases experience at least 1 SRE, which may reduce survival and add considerably to healthcare costs. Bone pain, the most common source of severe pain in these patients, can often be managed with analgesics or radiotherapy. However, treatment may be difficult because of associated side effects. Bisphosphonates palliate bone pain and can treat the underlying cause of the symptoms: malignant osteolysis. Preventing or delaying the onset of SREs is crucial because patients with an SRE have an increased risk of additional SREs, thereby reducing quality of life.
Metastatic bone disease is a tremendous burden on patients and society. Supportive therapy with zoledronic acid has shown benefits for patients with bone metastases by delaying the onset and reducing the incidence of SREs, thus preserving patients' quality of life and functional independence.
恶性骨病可导致具有临床意义的骨骼病变，对生活质量产生负面影响。本文将讨论骨转移引起的骨相关事件（SREs）的发生率和后果，以及骨转移治疗的效果。
通过PubMed和国际肿瘤学会议论文集对骨病负担进行研究。
恶性骨病是一种潜在的毁灭性疾病，在晚期癌症患者中很常见。大多数骨转移患者至少经历1次SRE，这可能会缩短生存期并大幅增加医疗成本。骨痛是这些患者严重疼痛的最常见来源，通常可用镇痛药或放射治疗来控制。然而，由于相关的副作用，治疗可能会很困难。双膦酸盐可缓解骨痛，并能治疗症状的根本原因：恶性骨溶解。预防或延迟SREs的发生至关重要，因为发生过SRE的患者再次发生SRE的风险增加，从而降低生活质量。
转移性骨病给患者和社会带来巨大负担。唑来膦酸的支持性治疗已显示出对骨转移患者有益，可延迟SREs的发生并降低其发生率，从而维持患者的生活质量和功能独立性。
